UNSPSC 51281804: Carubicin

This classification denotes an anthracycline antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E7437K3983. European Medicines Agency schedules Carubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06151MIG. Carubicin generally arises in the molecular formula C26H27NO10.

UNSPSC 51281804 Carubicin is a Commodity code nominally designating a pharmaceutical product, but recent state and local solicitations show minimal direct activity under this specific code. The code does not appear in the sourced opportunities; instead, state and local jurisdictions procure naloxone, drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and emergency medical supplies through broader pharmaceutical and medical-supply categories. When carubicin-specific procurement occurs, it is likely tagged within parent pharmaceutical or chemotherapy-drug families rather than at this narrow commodity level.

Recent activity under related pharmaceutical codes reflects solicitation by state health agencies, county health departments, and cities procuring drugs and medical supplies for community health, emergency response, and employee benefit programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities; Seminole County, Florida solicited naloxone and drug deactivation systems through IFB 60459723LAS (due July 26, 2023); the City of Tampa issued an ITB for medical and first aid supplies for the Fire Department Rescue Division (due March 13, 2026) with an estimated contract value of $700,000 and a 5 percent small local business enterprise set-aside; and the Texas Health and Human Services Commission issued an RFI in April 2026 to explore direct-to-manufacturer prescription programs. Geographic activity spans Florida, Texas, Minnesota, and participating cooperative-purchasing jurisdictions, but no solicitation in the source block targets carubicin explicitly.